Patent · US Expired

Use of VWF-containing concentrates as a therapy which is employed in combination with antithrombotic and fibrinolytic therapy

US5571784A · kind A · utility

7Cited by

7References

2Claims

0Family size

Assignee

Behringwerke Aktiengesellschaft · DE

Inventors

Martin Reers · Austin, US
Gerhard Dickneite · Marburg, DE

Key dates

Filing date	Oct 18, 1995
Grant date	Nov 5, 1996
Priority date	—
Expiry date	Oct 18, 2015

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P7/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the administration of von Willebrand factor (vWF)-containing drugs in association with the therapeutic use of blood anticoagulants, either on their own or together with fibrinolytics. The administration, which is for the purpose of reducing the risk of hemorrhages in patients, can take place either at the same time or following the anticoagulant and lytic treatment. A therapy principle is described which separates, during therapy, the desirable effect of anticoagulation and/or fibrinolysis from the undesirable side effect of hemorrhagic tendency.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.